Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions has proceeded uninterrupted by the pandemic and has been completed on time. The second phase of manufacturing the nanoparticle material is expected to continue on schedule as the Company makes ready for its first human study.
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
May 25, 2023
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session